Role of COX-1 and -2 in prostanoid generation and modulation of angiotensin II responses

Am J Physiol Heart Circ Physiol. 2003 Dec;285(6):H2399-410. doi: 10.1152/ajpheart.00294.2003.

Abstract

The role of cyclooxygenase (COX)-1 and -2 in prostanoid formation and modulation of pressor responses to ANG II was investigated in the pulmonary and systemic vascular beds in the rat. In the present study, selective COX-1 and -2 inhibitors attenuated increases in pulmonary arterial pressure and decreases in systemic arterial pressure in response to arachidonic acid but did not alter responses to PGE1 or U-46619. The selective COX-1 and -2 inhibitors did not modify systemic pressor responses to injections or infusions of ANG II or pulmonary pressor responses to injections of the peptide. COX-2 inhibitors did not alter, whereas a COX-1 inhibitor depressed, arachidonic acid-induced platelet aggregation. These data provide evidence in support of the hypothesis that prostanoid synthesis occurs by way of the COX-1 and -2 pathways in the pulmonary and systemic vascular beds but that pressor responses to ANG II are not mediated or modulated by these pathways in the rat.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid / pharmacology
  • Alprostadil / pharmacology
  • Angiotensin II / pharmacology*
  • Animals
  • Arachidonic Acid / pharmacology
  • Blood Pressure / drug effects
  • Blood Pressure / physiology
  • Cardiac Catheterization / methods
  • Cyclooxygenase 1
  • Cyclooxygenase 2
  • Cyclooxygenase 2 Inhibitors
  • Cyclooxygenase Inhibitors / pharmacology
  • Isoenzymes / metabolism*
  • Membrane Proteins
  • Nitrobenzenes / pharmacology
  • Platelet Aggregation / drug effects
  • Platelet Aggregation / physiology
  • Prostaglandin-Endoperoxide Synthases / metabolism*
  • Prostaglandins / biosynthesis*
  • Pulmonary Circulation / drug effects
  • Pulmonary Circulation / physiology*
  • Pyrazoles / pharmacology
  • Rats
  • Rats, Sprague-Dawley
  • Sulfonamides / pharmacology
  • Vasoconstrictor Agents / pharmacology*
  • Vasodilator Agents / pharmacology

Substances

  • 4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide
  • Cyclooxygenase 2 Inhibitors
  • Cyclooxygenase Inhibitors
  • Isoenzymes
  • Membrane Proteins
  • Nitrobenzenes
  • Prostaglandins
  • Pyrazoles
  • SC 560
  • Sulfonamides
  • Vasoconstrictor Agents
  • Vasodilator Agents
  • Angiotensin II
  • N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide
  • Arachidonic Acid
  • 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid
  • Cyclooxygenase 1
  • Cyclooxygenase 2
  • Prostaglandin-Endoperoxide Synthases
  • Ptgs1 protein, rat
  • Alprostadil